Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lorus Therapeutics has started the GLP toxicology studies for its lead anticancer small molecule drug LOR-253.
Subscribe to our email newsletter
The toxicology studies, which are currently underway, are designed to support the filing of an investigational new drug application with the FDA for LOR-253 to initiate a Phase I clinical study in cancer indications. Lorus intends to submit an IND for LOR-253 during the fourth quarter of 2008, following successful completion of the toxicology program.
LOR-253 is a proprietary small molecule compound discovered at Lorus and optimized for its anticancer properties. In preclinical studies, LOR-253 has shown selective and potent antitumor activity in a variety of human cancers, including colon cancer and non-small cell lung cancer, and has an excellent therapeutic window due to its low toxicity.
Aiping Young, president and CEO of Lorus, said: “LOR-253 is the first compound from our small molecule program to advance to GLP toxicology studies. Moving LOR-253 forward is consistent with Lorus’s focus on development of novel drugs from a broad range of technologies.”